ASX Announcement **15 April 2020**

Atomo receives additional order for COVID-19 test devices

COVID-19 test devices ordered to date: 947,200

SYDNEY Australia, 15 April 2020: Australian rapid blood test company Atomo Diagnostics Limited (**Atomo**) is pleased to announce that it has received a second purchase order from French diagnostics company, NG Biotech, SAS (NG Biotech) to supply an additional 550,000 integrated blood test devices for the rapid blood based testing of antibodies produced in response to COVID-19 for the period from May to July 2020.

This order follows an initial purchase order for 397,200 devices in late March 2020 and takes the total number of devices ordered to 947,200. As disclosed by Atomo in its second Supplementary IPO Prospectus, dated 31 March 2020, the supply agreement provides NG Biotech with the right to purchase up to a total of 2.465 million devices during calendar year 2020. Atomo and NG Biotech intend to enter into a further binding purchase agreement for the ongoing supply of Atomo products beyond 2020.

Atomo co-founder and Managing Director John Kelly said, "We are moving very quickly to respond to the interest in Atomo's rapid test devices for delivery of reliable, user friendly rapid blood based testing as part of the global response to the COVID-19 pandemic. Focus is currently on fulfilling the first two orders placed by NG Biotech, who are already supplying tests to the French Ministry of Defense. In parallel, we remain in discussions with two US based COVID-19 test manufacturers for supply of OEM test devices".

The NG Biotech rapid test is CE Marked for professional use for COVID-19 testing in Europe.

The Atomo rapid test device has already secured both professional and self-test approvals in Europe as an HIV screening rapid test and Atomo's HIV Self-Test is the only HIV product approved in Australia by the Therapeutic Goods Administration (TGA) for self-test use.

Atomo intends to bring forward the planned expansion of its production capacity in order to meet the anticipated ongoing demand for COVID-19 test devices and continue to support Atomo's existing HIV distributors and other OEM customers.

Atomo has raised A$30 million at a price of $0.20 per share in its initial public offering and its shares will commence quotation on the ASX at 11.00am on 16 April 2020 under the ASX code "AT1", with an undiluted market capitalisation of $112 million at the IPO price.

For more information, please contact:

Jane Lowe
IR Department
jane.lowe@irdepartment.com.au
Phone: +61 411 117 774

John Kelly
Atomo Diagnostics
john.kelly@atomodiagnostics.com
Phone: +61 401 922 279

This announcement was authorised by John Kelly, Managing Director.

About Atomo

Atomo Diagnostics Limited is an Australian medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo's patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers. Atomo has supply agreements in place for tests targeting infectious diseases including COVID-19, viral vs bacterial differentiation and female health.

See more at www.atomodiagnostics.com.